Europe’s medicines regulator said on Thursday it had added a rare nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson’s COVID-19 vaccine after it reviewed 108 cases reported worldwide.
“After assessing the available data, PRAC considered that a causal relationship between COVID-19 vaccine Janssen and GBS is possible,” the European Medicines Agency said, referring to its safety committee, PRAC.
Iran hits record for new COVID-19 cases for second day running
Explainer: US pays $4 bln to Afghan forces; Who is watching?
Mac Neil wins Canada’s first gold in Tokyo Games first in women’s 100 butterfly
Tunisian president relieves prime minister of his post, freeze parliament
Algeria reimposes restrictions on gatherings to stem COVID-19 cases
Asia7 days ago
India’s COVID-19 excess deaths surpass four million: research
Latin America7 days ago
Haiti arrests 3 cops, awaits new chief, while mourning Moise
Asia5 days ago
Man with coronavirus disguises as wife on Indonesian flight
U.S7 days ago
Extreme weather fuels Oregon wildfires; outside help sought
Europe5 days ago
Norway mourns 77 dead a decade after extremist attack
Middle East5 days ago
Israel to reimpose COVID-19 ‘Green Pass’ as Delta variant hits
Australia & NZ4 days ago
Sydney COVID-19 outbreak a ‘national emergency’ as cases spike
Health5 days ago
Europe Could Have Been Hit With COVID-19 Earlier Than China, New Study Reveals